STERIS (STE)
NYSE: STE
· Real-Time Price · USD
235.45
-0.78 (-0.33%)
At close: Jun 20, 2025, 3:59 PM
238.50
1.30%
After-hours: Jun 20, 2025, 05:40 PM EDT
STERIS Revenue Breakdown
| Period Ending | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|
| Product Revenue | 2.87B | 2.76B | 2.79B | 2.56B | 1.44B | 1.4B | 1.3B |
| Product Revenue Growth | +3.89% | -0.77% | +8.96% | +77.08% | +2.91% | +8.24% | n/a |
| Service Revenue | 2.59B | 2.37B | 2.17B | 2.03B | 1.66B | 1.63B | 1.49B |
| Service Revenue Growth | +8.98% | +9.31% | +7.08% | +21.92% | +2.20% | +9.55% | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|
| Ireland Revenue | 107.32M | 82.69M | 74.46M | 82.01M | 71.91M | 63.82M | 748.57M |
| Ireland Revenue Growth | +29.78% | +11.06% | -9.20% | +14.05% | +12.67% | -91.47% | n/a |
| Other Foreign Locations Revenue | 1.34B | 1.3B | 1.3B | 1.27B | 808.58M | 755.35M | 1.98B |
| Other Foreign Locations Revenue Growth | +3.07% | +0.59% | +1.78% | +57.58% | +7.05% | -61.79% | n/a |
| United States Revenue | 4.01B | 3.75B | 3.59B | 3.23B | 2.23B | 2.21B | n/a |
| United States Revenue Growth | +6.83% | +4.60% | +11.08% | +44.98% | +0.69% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 333.9M | 335.45M | 329.3M | 335.63M | 309.06M | 308.3M | 328.43M | 359.06M | 335.91M | 305.14M | 323.19M | 334.63M | 453.64M | 310.56M | 344.8M | 393.75M | 221.07M | 182.37M | 172.71M | 155.17M | 189.06M | 172.93M | 175.96M | 178.78M | 173.12M | 158.08M | 162.31M | 158.41M | 161.57M | 159.14M | 153.36M | 155.81M | 205.74M | 158.76M | 163.68M | 151.89M | 150.1M | 177.32M | 172.46M | 126.83M | 130.99M |
| Selling, General, and Administrative Revenue Growth | -0.46% | +1.87% | -1.89% | +8.59% | +0.25% | -6.13% | -8.53% | +6.89% | +10.08% | -5.59% | -3.42% | -26.23% | +46.07% | -9.93% | -12.43% | +78.11% | +21.22% | +5.60% | +11.30% | -17.93% | +9.33% | -1.72% | -1.58% | +3.27% | +9.51% | -2.61% | +2.47% | -1.96% | +1.53% | +3.77% | -1.58% | -24.27% | +29.59% | -3.01% | +7.77% | +1.19% | -15.35% | +2.82% | +35.97% | -3.17% | n/a |
| Research and Development Revenue | 27.69M | 27.36M | 27.03M | 25.57M | 27.46M | 25.25M | 26.27M | 25.5M | 26.39M | 25.51M | 24.93M | 24.75M | 26.1M | 24.82M | 18.83M | 18.19M | 17.51M | 16.44M | 16.14M | 16.23M | 17.23M | 16.49M | 16.25M | 15.59M | 15.88M | 15.17M | 15.77M | 16.22M | 17.61M | 15.2M | 13.97M | 14M | 15.76M | 14.59M | 14.62M | 14.43M | 14.31M | 14.33M | 14.26M | 13.77M | 14.18M |
| Research and Development Revenue Growth | +1.20% | +1.21% | +5.70% | -6.88% | +8.74% | -3.86% | +3.00% | -3.36% | +3.43% | +2.35% | +0.72% | -5.16% | +5.13% | +31.82% | +3.52% | +3.87% | +6.55% | +1.83% | -0.54% | -5.77% | +4.48% | +1.46% | +4.26% | -1.85% | +4.69% | -3.84% | -2.76% | -7.89% | +15.89% | +8.74% | -0.21% | -11.15% | +8.02% | -0.18% | +1.31% | +0.82% | -0.17% | +0.55% | +3.56% | -2.89% | n/a |